Published in Br J Pharmacol on November 01, 1994
Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med (1995) 2.83
Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res (2001) 1.38
Interleukin-5 modulates interleukin-8 secretion in eosinophilic inflammation. Mediators Inflamm (1998) 0.82
Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med (1988) 4.60
Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science (1989) 4.57
A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni. J Immunol (1979) 4.17
Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest (1991) 3.88
Interleukin-5, eosinophils, and disease. Blood (1992) 3.80
Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis (1985) 3.77
Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med (1988) 3.50
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest (1986) 2.90
Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med (1988) 2.71
Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5. Proc Natl Acad Sci U S A (1987) 2.55
Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci U S A (1990) 2.37
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol (1986) 2.29
Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc Natl Acad Sci U S A (1987) 2.22
Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. J Exp Med (1985) 2.22
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol (1991) 1.98
Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci U S A (1986) 1.93
Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci U S A (1987) 1.89
IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology (1990) 1.85
T lymphocyte activation in acute severe asthma. Lancet (1988) 1.81
Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80
Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis (1988) 1.77
Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol (1992) 1.63
Effects of leukotriene B4 inhalation. Airway sensitization and lung granulocyte infiltration in the guinea pig. Am Rev Respir Dis (1987) 1.25
Development of a prolonged eosinophil-rich inflammatory leukocyte infiltration in the guinea-pig asthmatic response to ovalbumin inhalation. Am Rev Respir Dis (1988) 1.20
Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis (1991) 1.17
Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs. Br J Pharmacol (1990) 1.14
Migration of primed human eosinophils across cytokine-activated endothelial cell monolayers. Blood (1992) 1.07
A comparison of eosinophil-activating factor (EAF) with other monokines and lymphokines. Eur J Immunol (1986) 1.03
Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung. Am Rev Respir Dis (1992) 1.03
Active immunization induces lung hyperresponsiveness in the guinea pig. Pharmacologic modulation and triggering role of the booster injection. Am Rev Respir Dis (1988) 1.02
Modulation of eosinophil chemotaxis by interleukin-5. Am J Respir Cell Mol Biol (1992) 1.00
In vitro and in vivo chemotaxis of guinea pig leukocytes toward leukotriene B4 and its w-oxidation products. Prostaglandins (1985) 0.98
Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. Inhibition by ketotifen. Am Rev Respir Dis (1988) 0.97
The appearance of hypodense eosinophils in antigen-dependent late phase asthma. Am Rev Respir Dis (1989) 0.96
Activation of guinea pig eosinophils by human recombinant IL-5. Selective priming to platelet-activating factor-acether and interference of its antagonists. J Immunol (1991) 0.94
The human eosinophil in inflammation. Agents Actions (1990) 0.88
Protection by nedocromil sodium of active immunization-induced bronchopulmonary alterations in the guinea pig. Am Rev Respir Dis (1990) 0.87
T-cell-dependent accumulation of eosinophils in the lung and its inhibition by monoclonal anti-interleukin-5. Int Arch Allergy Appl Immunol (1991) 0.86
Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate. Br J Pharmacol (1990) 0.86
Immunopathologic alterations in the bronchi of immunized guinea pigs. Am J Respir Cell Mol Biol (1993) 0.84
LTB4, a potent chemotactic factor for purified guinea-pig eosinophils: interference of PAF-acether antagonists. Int J Immunopharmacol (1991) 0.84
Cytokine regulation of eosinophil function. Clin Immunol Immunopathol (1992) 0.83
Heterogeneity of human eosinophils. J Allergy Clin Immunol (1989) 0.81
Density profile of bronchoalveolar lavage eosinophils in the guinea pig model of allergen-induced late-phase allergic responses. Am J Respir Cell Mol Biol (1992) 0.80
Airway eosinophils from actively sensitized guinea pigs exhibit enhanced superoxide anion release in response to antigen challenge. Am J Respir Cell Mol Biol (1991) 0.78
Effect of human recombinant interleukin-5 on in vitro responsiveness to PAF of lung from actively sensitized guinea-pigs. Br J Pharmacol (1992) 0.77
Perspectives in platelet-activating factor research. Pharmacol Rev (1987) 5.27
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet (2000) 5.04
Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2. Nat New Biol (1973) 3.41
Release of vasoactive substances from guinea-pig lungs by slow-reacting substance c and arachidonic acid. Its blockade by nonsteroid anti-inflammatory agents. Pharmacology (1971) 3.12
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol (1980) 2.90
Selective inhibition by mepacrine of the release of "rabbit aorta contracting substance" evoked by the administration of bradykinin. J Pharm Pharmacol (1972) 2.37
The role of platelet-activating factor in platelet aggregation. Nature (1979) 2.37
Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut (2002) 2.31
Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci (1981) 2.22
Acute myocardial infarction: can it be a complication of acute organophosphorus compound poisoning? J Postgrad Med (2013) 2.15
Suppression of asthma-like responses in different mouse strains by oral tolerance. Am J Respir Cell Mol Biol (2001) 1.95
A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer (2001) 1.95
Requirement for gammadelta T cells in allergic airway inflammation. Science (1998) 1.93
Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis (1988) 1.77
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res (2001) 1.74
A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol (1999) 1.67
Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys (1996) 1.63
p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology (2000) 1.52
Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect Immun (1994) 1.50
Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest (1995) 1.49
Murine models of asthma. Eur Respir J (2003) 1.49
Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data. Pathology (2015) 1.47
Pathology reporting of breast cancer: trends in 1989-1999, following the introduction of mammographic screening in Western Australia. Pathology (2005) 1.44
Eosinophil recruitment into the respiratory epithelium following antigenic challenge in hyper-IgE mice is accompanied by interleukin 5-dependent bronchial hyperresponsiveness. Proc Natl Acad Sci U S A (1995) 1.43
Role of platelets in aspirin-sensitive bronchoconstriction in the guinea-pig; interactions with salicylic acid. Br J Pharmacol (1978) 1.43
The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. Br J Pharmacol (1984) 1.42
Inhaled nitric oxide does not improve cardiac or pulmonary function in patients with an exacerbation of chronic obstructive pulmonary disease. Crit Care Med (1999) 1.39
Pre-operative chemo-radiotherapy in locally advanced rectal cancer: is this the way of future management? Australas Radiol (1999) 1.38
Systemic administration of endotoxin induces bronchopulmonary hyperreactivity dissociated from TNF-alpha formation and neutrophil sequestration into the murine lungs. J Immunol (1998) 1.33
Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer (2000) 1.29
Effect of acute moderate changes in PaCO2 on global hemodynamics and gastric perfusion. Crit Care Med (2000) 1.28
Mianserin hydrochloride: peripheral and central effects in relation to antagonism against 5-hydroxytryptamine and tryptamine. Eur J Pharmacol (1972) 1.24
Control of sexually transmitted diseases in Haiti: results and implications of a baseline study among pregnant women living in Cité Soleil Shantytowns. J Infect Dis (1995) 1.23
Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J Exp Med (1994) 1.22
Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis (2008) 1.21
A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology (1996) 1.21
Golgi complex reorganization during muscle differentiation: visualization in living cells and mechanism. Mol Biol Cell (2001) 1.19
Rapid increase in bone-marrow eosinophil production and responses to eosinopoietic interleukins triggered by intranasal allergen challenge. Am J Respir Cell Mol Biol (1997) 1.18
ORG 6001 (3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride), a steroidal anti-arrhythmic agent. J Pharm Pharmacol (1975) 1.17
Inhibition by sulfhydryl agents of arachidonic acid-induced platelet aggregation and release of potential inflammatory substances. Prostaglandins (1974) 1.16
Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol (1981) 1.15
Selective Mycobacterium avium-induced production of nitric oxide by human monocyte-derived macrophages. J Leukoc Biol (1994) 1.13
Ultrastructural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. Br J Exp Pathol (1985) 1.12
Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol (1980) 1.12
Platelet activation--a role for a 40K anti-phospholipase A2 protein indistinguishable from lipocortin. Nature (1986) 1.11
Skin eosinophilia in atopic patients. J Allergy Clin Immunol (1988) 1.11
Interference by the novel PAF-acether antagonist WEB 2086 with the bronchopulmonary responses to PAF-acether and to active and passive anaphylactic shock in guinea-pigs. Eur J Pharmacol (1987) 1.11
Anaphylactic bronchoconstriction in BP2 mice: interactions between serotonin and acetylcholine. Br J Pharmacol (1999) 1.10
Assessment of the accuracy of transrectal ultrasonography in anorectal neoplasia. Br J Surg (2003) 1.10
Pharmacological modulation of Paf-induced rat pleurisy and its role in inflammation by zymosan. Br J Pharmacol (1989) 1.05
Blockade of the inflammatory effects of platelet-activating factor by cyclo-oxygenase inhibitors. Braz J Med Biol Res (1981) 1.04
Diffuse optical tomography of pain and tactile stimulation: activation in cortical sensory and emotional systems. Neuroimage (2008) 1.03
Role of eosinophil activation in the bronchial reactivity of allergic guinea pigs. Am J Respir Crit Care Med (1994) 1.03
Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether). Eur J Pharmacol (1982) 1.02
Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. Thromb Res (1982) 1.02
Generation of an eosinophilotactic activity in the pleural cavity of platelet-activating factor-injected rats. J Pharmacol Exp Ther (1991) 1.02
Carrageenan and thrombin trigger prostaglandin synthetase-independent aggregation of rabbit platelets: inhibition by phospholipase A2 inhibitors. J Pharm Pharmacol (1977) 1.02
Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig. Eur J Pharmacol (1986) 1.02
Active immunization induces lung hyperresponsiveness in the guinea pig. Pharmacologic modulation and triggering role of the booster injection. Am Rev Respir Dis (1988) 1.02
Platelets mediate the action of diethylcarbamazine on microfilariae. Nature (1987) 1.02
Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet (1986) 1.02
Involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021. Lancet (1985) 1.01
Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked. Biochem J (1985) 1.01
Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest (1998) 1.01
Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity. J Immunol (1996) 1.01
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol (1995) 1.01
Upregulation by glucocorticoids of responses to eosinopoietic cytokines in bone-marrow from normal and allergic mice. Br J Pharmacol (2000) 1.00
Salicylic acid fails to inhibit generation of thromboxane A2 activity in platelets after in vivo administration to the rat. J Pharm Pharmacol (1978) 1.00
Acute hypotension due to carrageenan, arachidonic acid and slow reacting substance C in the rabbit: role of platelets and nature of pharmacological antagonism. Eur J Pharmacol (1977) 1.00
In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs. J Clin Invest (1996) 0.98
Blockade by fenspiride of endotoxin-induced neutrophil migration in the rat. Eur J Pharmacol (1993) 0.96
Desensitization to PAF-induced bronchoconstriction and to activation of alveolar macrophages by repeated inhalations of PAF in the guinea pig. Biochem Biophys Res Commun (1985) 0.96
Endotoxins, asthma, and allergic immune responses. Toxicology (2000) 0.96
The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer (2009) 0.96
Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. Eur J Pharmacol (1982) 0.95
Histamine and leukotriene-independent guinea-pig anaphylactic shock unaccounted for by Paf-acether. Br J Pharmacol (1985) 0.95
Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. Br J Pharmacol (1984) 0.95
Differences in local conformation around cysteine residues in alpha alpha, alpha beta, and beta beta rabbit skeletal tropomyosin. Arch Biochem Biophys (1987) 0.94
Activation of guinea pig eosinophils by human recombinant IL-5. Selective priming to platelet-activating factor-acether and interference of its antagonists. J Immunol (1991) 0.94
Inhibition by aspirin of bronchoconstriction due to leukotrienes C4 and D4 in the guinea pig. Eur J Pharmacol (1981) 0.93
A genome-wide screen for asthma-associated quantitative trait loci in a mouse model of allergic asthma. Hum Mol Genet (1999) 0.93
A novel structural basis for membrane association of a protein: construction of a chimeric soluble mutant of (S)-mandelate dehydrogenase from Pseudomonas putida. Biochemistry (1993) 0.93
Short-term effects of prone position in critically ill patients with acute respiratory distress syndrome. Intensive Care Med (1997) 0.93
Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis (2013) 0.93
Intravenous injections of PAF-acether induce platelet aggregation in rats. Eur J Pharmacol (1988) 0.92
Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. Thromb Res (1982) 0.91
The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer (2004) 0.91
Drug modulation of antigen-induced paw oedema in guinea-pigs: effects of lipopolysaccharide, tumour necrosis factor and leucocyte depletion. Br J Pharmacol (1994) 0.90
Pharmacological evidence for a vasodilator receptor to serotonin in the nasal vessels of the dog. Eur J Pharmacol (1974) 0.90
Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) (2003) 0.90
Pharmacological modulation of the respiratory and haematological changes accompanying active anaphylaxis in the guinea-pig. Eur J Pharmacol (1986) 0.90
1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle. Biochim Biophys Acta (1985) 0.90